Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...

Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...

Shares of Amgen (Nasdaq: AMGN) started crashing in early November and didn’t improve when the company released data from a ...

AbbVie is a resurging Dividend King. Amgen's recent clinical setback makes its stock available at a discount. Gilead Sciences is a steady dividend payer with a growing payout. For a while, though, ...

Amgen's diversified portfolio includes 14 blockbuster medicines, with standout growth in Repatha and Evenity, and promising pipeline developments, particularly for MariTide. Despite patent ...

(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...